Novartis to Present New Data on Potential Lymphoma Treatments

Novartis to Present New Data on Potential Lymphoma Treatments

Novartis will present the most recent clinical data from its cancer research program at the upcoming 58th American Society of Hematology (ASH) Annual Meeting & Exposition Dec. 3-6 in San Diego and at the San Antonio Breast Cancer Symposium (SABCS) Dec. 6-10 in San Antonio.

Presentations will focus on potential treatment approaches for a number of cancers, including leukemia and lymphoma.

“Novartis continues to invest in not only creating new medicines for underserved patient communities, but also in redefining cancer treatment goals,” Bruno Strigini, CEO of Novartis Oncology, said in a news release. “Our ASH and SABCS data, including personalized cell and targeted therapies of the future, underscore our core belief in treating each patient as an individual, not just the disease.”

Regarding potential treatments for lymphoma, Novartis will present data from two studies. One of the presentations, titled “A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma,” will showcase the first results of the ongoing ASSIST_FL study (NCT01419665; conducted by Sandoz).

The study was designed to evaluate the effectiveness of the rituximab biosimilar GP2013 compared to Rituxan (rituximab) as first-line therapy for patients with advanced follicular lymphoma.

The other presentation, “Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, “Double Hit” Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas,” will focus on the Phase 2 JULIET (NCT02445248) trial, investigating the effectiveness and safety of CTL019 in adult patients with relapsed or refractory diffuse large B cell lymphomas (DLBCL).

CTL019 is a CAR T-cell therapy that consists of taking a patient’s own T-cells (immune cells) and genetically modifying them so they can specifically identify and kill cancer cells expressing the CD19 protein, widely expressed in B-cell lymphomas. The patient’s modified cells are then reintroduced into the body. The JULIET study is currently recruiting patients.

Other presentations from Novartis to be presented at the two meetings include data on other cancer types, such as leukemia, myelofibrosis, and breast cancer, as well as chronic iron overload.

Leave a Comment

Your email address will not be published. Required fields are marked *